Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Catalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Breakthrough chiral phosphoric acid catalysis enables high-yield production of N-N axis chiral pyrrole derivatives with exceptional enantioselectivity against QGP-1 tumor cells.
Innovative rare earth metal cluster catalysis enables solvent-free amide synthesis with high yields and broad substrate scope enhancing supply chain reliability for pharmaceutical intermediates
Patent CN115197124B enables mild ammonium iodide-catalyzed pyridine synthesis with broad substrate scope, delivering cost-effective manufacturing and reliable supply chain for pharmaceutical intermediates.
This patent introduces a highly enantioselective synthesis of chiral indoxazinone compounds with mild conditions enabling cost reduction and reliable supply for pharmaceutical intermediates manufacturing.
Patent CN111534832A enables catalyst-free sulfoxide synthesis via electrocatalysis ensuring high purity while reducing environmental impact for pharmaceutical supply chains.
Patent CN116082217B introduces a novel synthesis for N-N axis chiral bisindole compounds with high enantioselectivity and yield enabling cost-effective manufacturing and reliable supply for pharmaceutical applications
Novel indole-skeleton phosphine ligand enables high-yield C-S bond formation with reduced catalyst loading, offering significant supply chain reliability for pharmaceutical intermediates.
Patent CN108341740A introduces a green synthesis of p-Menthane-3,8-diol using graphene oxide catalyst without strong acids. This method delivers enhanced purity and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN120247882B introduces a mild one-step synthesis method for nitrogen heterocycle-derived polyarylmethane antitumor compounds with high MCF-7 cytotoxicity enabling significant cost reduction and scalable pharmaceutical manufacturing.
Patent CN120247882B enables mild organocatalytic production of cytotoxic compounds against MCF-7 cells with scalable manufacturing advantages.
Patent CN108558692B enables efficient amide bond formation under mild conditions with high yields, offering sustainable cost reduction and reliable supply chain for pharmaceutical intermediates.
Novel chiral phosphoric acid catalysis enables high-yield enantioselective synthesis of oncology intermediates with enhanced supply chain reliability and cost efficiency.
Novel chiral phosphoric acid-catalyzed synthesis enables scalable production of high-purity oncology intermediates with enhanced diastereoselectivity and cost-effective manufacturing processes.
Patent CN117088826B enables visible-light synthesis of polysubstituted oxazoles without transition metals, offering greener manufacturing and enhanced supply chain reliability for pharmaceutical intermediates.
Patent CN110452150B enables one-step asymmetric synthesis under mild conditions with exceptional optical purity, delivering significant cost reduction and supply chain reliability for chiral catalyst manufacturing.
Patent CN104447690B enables high-purity agrochemical intermediate synthesis through one-pot methodology, reducing waste and enhancing supply chain reliability for global manufacturers.
Novel Mo/Cu-catalyzed synthesis enables scalable production of high-purity trifluoromethyl triazoles with simplified manufacturing and enhanced supply chain reliability for pharmaceutical applications.
Patent CN118930570B enables room-temperature synthesis of isoindolinone derivatives with high yield and purity delivering significant cost reduction supply chain reliability
Patent CN112209947A enables high-yield enantioselective production of cytotoxic indoxazinones with mild conditions enhancing supply chain reliability for anti-tumor drug manufacturing.
Patent CN113880781B enables scalable biomass-derived synthesis of trifluoromethyl triazoles with mild conditions and high purity. Delivers supply chain reliability and significant cost reduction for pharma intermediates.